Associate Director, CMC, Drug Product

Who We Are

Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.

Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.

We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.

Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.

In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN
1701 and XEN
1720 (targeting Nav
1.7) and XEN
1120 (targeting Kv7), which are being developed for pain. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.

We are seeking an Associate Director, CMC, Drug Product, to join our team. The Associate Director, CMC, Drug Product will manage and oversee the early-stage assessment and formulation development of drug products pre-clinical and early-stage Phase 1 and 2 clinical programs. The candidate will be a key member of highly collaborative internal Drug Product and CMC teams, primarily managing discovery and toxicology formulation, develop ability evaluation of candidate molecules, and Phase 1 and 2 formulation and manufacturing process development.

This position reports to the Director, CMC, Drug Product and will be based out of our Boston, MA, USA in our Needham office. We may consider other jurisdictions for exceptional candidates. This role is a hybrid position, requiring a minimum of 2 days per week in the office.

• Lead non-clinical formulation and early phase clinical formulation and process development activities of small molecule drug products. Effectively communicate with cross-functional teams to ensure CMC decisions support current and upcoming phases of drug development.
• Manage activities related to early-stage formulation development including drug substance attribute profiling, develop ability assessments and executing plans for first in human phase 1 and phase 2 formulation development. Provide updates to product development teams…